|
US2021046071A1
|
|
Tetracyclic compounds and their salts, compositions, and methods for their use
|
|
WO2021030686A1
|
|
Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
|
|
WO2020081971A1
|
|
Combinations for immune-modulation in cancer treatment
|
|
CA3088998A1
|
|
Quinolone analogs and their salts, compositions, and method for their use
|
|
EP3377068A1
|
|
Combination therapy of tetracyclic quinolone analogs for treating cancer
|
|
EP3394070A1
|
|
Crystalline forms of quinolone analogs and their salts
|
|
US2017166590A1
|
|
Crystalline forms of quinolone analogs and their salts
|
|
TW201720832A
|
|
Crystalline forms of quinolone analogs and their salts
|
|
TW201531473A
|
|
Pyrazolopyrimidine prodrugs and methods of use
|
|
WO2012170827A2
|
|
Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
|
|
AU2010326268A1
|
|
Pyrazolopyrimidines and related heterocycles as CK2 inhibitors
|
|
NZ630353A
|
|
Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
|
|
CN102497862A
|
|
Combination therapies with ck2 modulators
|
